Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06422715
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-22
First Post:
2024-05-07
Brief Title:
PTLD Multicentric Retrospective Study
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Fondazione Italiana Linfomi - ETS
Study Overview
Official Title:
Post-transplant Lymphoproliferative Disorders PTLD Multicentric Observational Retrospective Cohort Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FIL_PTLD
Brief Summary:
This is a multicentric observational retrospective cohort study of patients with histological diagnosis of PTLD
The aim of the study is to analyze the clinical features and survival of patients who received a PTLD diagnosis with the target to assess a survival outcome to obtain an epidemiologic and clinical characterization of the subpopulations affected by PTLD to recognize unfavorable properties to report the current treatment strategies to provide rationale for the design of a prospective registry in order to develop future novel treatments
The aim of the study is to analyze the clinical features and survival of patients who received a PTLD diagnosis with the target to assess a survival outcome to obtain an epidemiologic and clinical characterization of the subpopulations affected by PTLD to recognize unfavorable properties to report the current treatment strategies to provide rationale for the design of a prospective registry in order to develop future novel treatments
Detailed Description:
This is a multicentric observational retrospective cohort study of patients with histological diagnosis of PTLD Retrospective data will be collected for all cases of PTLD diagnosed during a 10 years period since 1st January 2011 to 31th December 2021
The following clinical characteristics of the patient at the time of PTLD diagnosis and pathology will be taken into consideration positivity of EBV virus serum LDH concentration PTLD subtype early lesion polymorphic or monomorphic PTLD lymphoma histotype stage of disease according to the Ann Arbor classification and localization nodal or extranodal immunosuppressive regimen taken by the patient since the transplant therapeutic approach adopted and response obtained
The following clinical characteristics of the patient at the time of PTLD diagnosis and pathology will be taken into consideration positivity of EBV virus serum LDH concentration PTLD subtype early lesion polymorphic or monomorphic PTLD lymphoma histotype stage of disease according to the Ann Arbor classification and localization nodal or extranodal immunosuppressive regimen taken by the patient since the transplant therapeutic approach adopted and response obtained
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None